SouthViews No. 298, 6 October 2025
A Revolution in HIV/AIDS Treatment
By German Velasquez
On September 24, 2025, two agreements were announced with generic drug manufacturers in India for the supply of generic lenacapavir at $40 (instead of the original $28,218) per patient per year. However, these generics can only be supplied to the countries included in Gilead’s voluntary license, excluding too many from accessing this price.
